Neo-MASCT Immunotherapy for Advanced NSCLC.

Inclusion Criteria: 1. The age is 18 to 80 years old. 2. The failure standard treatment subjects with advanced or relapsed NSCLC. 3. Informed consent of the patient/legal representative was signed. 4. Other anti-cancer treatments are at least one month apart from the study . 5. The eastern cancer cooperative group (ECOG) was rated 0-2. 6. According to the The reaction of solid tumors v1.1 (RECIST1.1 standard), there must be at least one measurable lesion . 7. The baseline blood and biochemical targets met the following criteria: The hemoglobin ≧ 85g/L ;White blood cells ≧ 3.0 x10 \^ 9 / L;Platelet ≧ 50 x10 \^ 9 / L;alanine aminotransferase (ALT), serum aspartate transaminase(AST) ≦ 2.5 times normal value limit; For patients with live metastases, ALT and AST are five times the normal limit; The alkaline phosphatase(ALP) ≦ 2.5 times the normal value; Serum bilirubin less than 1.5 times the normal value limit; Exclusion Criteria: 1. Participate in the planning or implementation of the research . 2. In addition to other clinical studies, unless it is an observational clinical study . 3. Being pregnant or planning a pregnancy. 4. Refuse to provide a blood specimen . 5. Allergic to sodium hydroquinone . 6. There is a history of organ transplantation 7. Brain transfer of the active period 8. Immunosuppressant drugs are currently in use or within 14 days prior to treatment. 9. The following exceptions are:Nasal, inhaled, topical use of steroid, or topical steroids (such as interjoint injection) . 10. Use a corticosteroid, no more than 10mg/day of prednisolone or its equivalent . 11. The use of steroids as a preventative treatment for hypersensitivity (such as CT scans) .